(Q34712338)

4 August 2017

1 reference

title

Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials (English)

1 reference

4 August 2017

D P Chew

1

1 reference

4 August 2017

D L Bhatt

series ordinal

2

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Internal Medicine Journal

4 August 2017

published in

1 reference

4 August 2017

volume

32

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

338-345

1 reference

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Platelet GPIIb-IIIa blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Potential non-glycoprotein IIb/IIIa effects of abciximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1445-5994.2002.00226.X

10.1046/J.1445-5994.2002.00226.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference